Friedreich's Ataxia (FRDA) 2017: Treatment Algorithm & Competitive Landscape - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Friedreich's Ataxia - Treatment Algorithm and Competitive Landscape 2017" report has been added to ResearchAndMarkets.com's offering.

According to the report, Friedreich ataxia (FRDA) is the most common inherited ataxia in Europe, the Middle East, South Asia (Indian subcontinent), and North Africa. It is estimated to affect 1 in 40,000 people in the United States.

Currently, there are more than 20 active pipeline products undergoing development in different clinical stages. Even at this stage there is no cure for this problem, available treatments are only focused on reducing the symptoms of disease effectively.

Phase Analysis

• Some drugs that are currently in the pipeline Phase II include: RT001 (Retrotope), Epicatechin (Cardero Therapeutics), ABT-RTA 408 (Reata Pharmaceuticals), JOT101 (Jupiter Orphan Therapeutics), TAK-831 (Takeda), and Vatiquinone (Edison Pharmaceuticals).
• 3 drugs are in phase I; 11 in preclinical and 3 in discovery phase.
• Currently, there are no drugs in the clinical phase III for the treatment of Friedreich's Ataxia.

There are several guidelines for the management and treatment of the disease provided by various clinicians:

• Europe - European Federation of neurological societies Guidelines
• Australia - National Health and Medical Research Council (NHMRC) Australia
• US - Friedreich's Ataxia Research Alliance (FARA), Consensus Clinical Management Guidelines for Friedreich's Ataxia
  

Companies Featured

• Cardero Therapeutics
• Chondrial Therapeutics
• Edison Pharmaceuticals
• Jupiter Orphan Therapeutics
• Reata Pharmaceuticals
• Retrotope
• Shire
• Takeda
• and more...

Key Topics Covered

1. Friedreich's Ataxia
2. Disease Overview
3. Cause
4. Pathophysiology
5. Pathogenesis
6. Symptoms
7. Diagnosis
8. Treatment and Management
9. Management of Friedreich's Ataxia
10. Diagnosis
11. Clinical Diagnosis
12. Genetic Diagnosis
13. Genotype-phenotype correlation
14. Genetic Testing
15. International Guidelines for the clinical management of Friedreich's ataxia and Treatment Algorithm
16. United States
17. Guidelines based on the different components of Friedreich ataxia
18. Guidelines for treatment
19. Guidelines in other countries
20. Pipeline Therapeutics
21. Comparative Analysis
22. Mid Stage Products (Phase II)
23. Comparative Analysis
24. RT001: Retrotrope
25. Product Description
26. Research and development
27. Product Development Activities
28. Epicatechin: Cardero Therapeutics
29. Product Description
30. Research and development
31. Vatiquinone: BioElectron
32. Product Description
33. Research and development
34. Product Development Activities
35. TAK-831: Takeda
36. Product Description
37. Research and Development
38. Inactive Products
39. Dormant Drugs
40. Drivers and Barriers

For more information about this report visit https://www.researchandmarkets.com/research/mczlss/friedreichs?w=4